The glucocorticoid-Angptl4-ceramide axis induces insulin resistance through PP2A and PKCζ. by Chen, Tzu-Chieh et al.
UC Berkeley
UC Berkeley Previously Published Works
Title
The glucocorticoid-Angptl4-ceramide axis induces insulin resistance through PP2A and 
PKCζ.
Permalink
https://escholarship.org/uc/item/5wm9r9sd
Journal
Science signaling, 10(489)
ISSN
1945-0877
Authors
Chen, Tzu-Chieh
Benjamin, Daniel I
Kuo, Taiyi
et al.
Publication Date
2017-07-25
DOI
10.1126/scisignal.aai7905
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
SC I ENCE S I GNAL ING | R E S EARCH ART I C L EMETABOL I SM1Metabolic Biology Graduate Program, University of California, Berkeley, Berkeley,
CA 94720–3104, USA. 2Department of Nutritional Sciences and Toxicology, Uni-
versity of California, Berkeley, Berkeley, CA 94720–3104, USA. 3Endocrinology
Graduate Program, University of California, Berkeley, Berkeley, CA 94720–3104,
USA. 4Departments of Chemistry and Molecular and Cell Biology, University of
California, Berkeley, Berkeley, CA 94720–3104, USA.
*Corresponding author. Email: walwang@berkeley.edu
Chen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017Copyright © 2017
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim
to original U.S.
Government WorksD
oThe glucocorticoid-Angptl4-ceramide axis induces
insulin resistance through PP2A and PKCz
Tzu-Chieh Chen,1,2 Daniel I. Benjamin,1,2 Taiyi Kuo,2,3 Rebecca A. Lee,2,3 Mei-Lan Li,2 Darryl J. Mar,2
Damian E. Costello,2,3 Daniel K. Nomura,1,2,3,4 Jen-Chywan Wang1,2,3*
Chronic glucocorticoid exposure is associated with the development of insulin resistance. We showed that
glucocorticoid-induced insulin resistance was attenuated upon ablation of Angptl4, a glucocorticoid target gene
encoding the secreted protein angiopoietin-like 4, which mediates glucocorticoid-induced lipolysis in white adipose
tissue. Throughmetabolomic profiling, we revealed that glucocorticoid treatment increased hepatic ceramide con-
centrations by inducing enzymes in the ceramide synthetic pathway in anAngptl4-dependentmanner. Angptl4was
also required for glucocorticoids to stimulate the activities of the downstream effectors of ceramide, protein phos-
phatase 2A (PP2A) andprotein kinase Cz (PKCz).We further showed that knockdownof PP2Aor inhibition of PKCz or
ceramide synthesis prevented glucocorticoid-induced glucose intolerance in wild-type mice. Moreover, the inhibi-
tion of PKCz or ceramide synthesis did not further improve glucose tolerance in Angptl4−/− mice, suggesting that
these molecules were major downstream effectors of Angptl4. Overall, our study demonstrates the key role of
Angptl4 in glucocorticoid-augmented hepatic ceramide production that induces whole-body insulin resistance.w
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 INTRODUCTION
Insulin resistance is a major risk factor for type 2 diabetes and cardio-
vascular diseases. Chronic and/or excess glucocorticoid exposure has
been associated with the development of insulin resistance (1–3). Glu-
cocorticoids reduce insulin-stimulated glucose utilization in skeletal
muscle andwhite adipose tissue (WAT). Glucocorticoid exposure also
suppresses insulin responsiveness in the liver and potentiates gluco-
neogenesis, which is inhibited by insulin. Several mechanisms have
been proposed to explain glucocorticoid-induced insulin resistance.
One mechanism is that glucocorticoids directly inhibit insulin
signaling and insulin-stimulated glucose uptake in myotubes and adi-
pocytes (4–7). A second mechanism is that osteocalcin secreted from
bone promotes insulin secretion and sensitivity (8). A third mecha-
nism is that lipolysis in WAT induced by glucocorticoids leads to in-
sulin resistance. Several lines of evidence support this mechanism.
Administration of acipimox, an inhibitor of WAT lipolysis, reduces
glucocorticoid-induced insulin resistance inhumans (9). Similarly, inject-
ing nicotinic acid into male Sprague-Dawley rats to decrease WAT
lipolysis corrects the antagonistic effects of glucocorticoids on insulin
actions (10). A finalmechanism is that glucocorticoid treatment increases
hepatic ceramide concentrations. One line of evidence supporting this
mechanism is that inhibition of ceramide synthesis by the small-molecule
inhibitor myriocin compromises glucocorticoid-induced insulin resist-
ance (11). Also, the ability of glucocorticoids to cause insulin resistance
is reduced inmice lackingDes2, an enzyme in the ceramide biosynthesis
pathway (11).
The biological responses of glucocorticoids aremainlymediated by the
glucocorticoid receptor, which directly regulates its primary target genes.
Therefore, to understand themolecular mechanism of glucocorticoid-
induced insulin resistance, the first step is to identify glucocorticoid
receptor primary target genes that participate in this glucocorticoid-regulated process. We have previously identified Angptl4 (which en-
codes angiopoietin-like 4) as a glucocorticoid receptor primary target
gene in hepatocytes and adipocytes (12, 13). TheAngptl4 gene encodes
a secreted protein that promotes lipolysis in adipocytes (14) and inhib-
its extracellular lipoprotein lipase (LPL) (15, 16). Angptl4−/− mice
display impaired glucocorticoid-induced WAT lipolysis (14) and are
therefore excellent models for assessing the role of WAT lipolysis in
glucocorticoid-modulated metabolite changes in peripheral tissues
that cause insulin resistance.
Here, we analyzed the effects of glucocorticoids on glucose ho-
meostasis and insulin actions in Angptl4−/− mice. We also performed
metabolomics in the liver and skeletal muscle of Angptl4+/+ (which will
be called wild-type mice) and Angptl4−/− mice treated with or without
glucocorticoids. Our goal was to establish Angptl4 as a glucocorticoid
receptor primary target gene that potentially links glucocorticoid-
promoted WAT lipolysis to the changes of insulin resistance–inducing
metabolites in the liver and/or skeletal muscle and to elucidate the
mechanism governing this process.RESULTS
Glucocorticoid-induced insulin resistance was improved in
Angptl4−/− mice
Wild-type and Angptl4−/− mice were treated with or without dexa-
methasone (a synthetic glucocorticoid) for 7 days. Intraperitoneal glucose
tolerance tests (IPGTTs) showed that in the absence of dexamethasone
treatment, there was no significant difference in basal glucose tolerance
betweenwild-type andAngptl4−/−mice (Fig. 1,A andB).Dexamethasone
treatment induced glucose intolerance in wild-type mice, as expected,
but not inAngptl4−/−mice (Fig. 1, A andB). Furthermore, fasting plasma
insulin concentrations were markedly higher in dexamethasone-treated
wild-typemice than those in untreatedwild-type andAngptl4−/−mice or
in dexamethasone-treated Angptl4−/− mice (Fig. 1C, 0 min). These
results confirmed that dexamethasone treatment inmice caused insulin
resistance resulting in hyperinsulinemia.Moreover, the decreased glu-
cose tolerance in dexamethasone-treated wild-type mice despite the
presence of hyperinsulinemia suggested that pancreatic islet b cells
could not compensate for insulin resistance. In untreated wild-type1 of 11
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 and Angptl4−/− mice, plasma insulin concentrations were increased
15min after glucose administration but returned to basal valueswithin
30 min (Fig. 1C). In dexamethasone-treated wild-type mice, plasma
insulin concentrations were similar at all three time points measured
(Fig. 1C). In dexamethasone-treated Angptl4−/− mice, plasma insulin
concentrations remained high 30 min after glucose administration
(Fig. 1C). This sustained increase in plasma insulin inAngptl4−/−mice
presumably overcame insulin resistance, explaining the normal glucose
tolerance of dexamethasone-treated Angptl4−/−mice. This finding sug-
gested that, in contrast to wild-type mice, pancreatic islet b cells of
Angptl4−/−mice could better compensate than those in wild-type mice
for the presence of insulin resistance. The lack of difference in insulin
concentrations between dexamethasone-treated Angptl4−/− or wild-
typemice at the 30-min time point in the IPGTT again demonstrated
that dexamethasone-treated wild-typemice were more severely glucose-
intolerant than Angptl4−/− mice.
To further assess whether Angptl4 depletion could protect mice
from glucocorticoid-induced insulin resistance, we performed insulin
tolerance tests (ITTs) to monitor and compare the dexamethasone
effect on whole-body insulin sensitivity of wild-type and Angptl4−/−
mice. Dexamethasone treatment significantly worsened insulin toler-
ance in wild-type mice (Fig. 1, D and E). Angptl4−/− mice were less
insulin-tolerant than wild-type mice in the absence of dexamethasone
treatment (Fig. 1, D and E). However, dexamethasone-treatedAngptl4−/−
mice had similar insulin tolerance to control wild-type mice and lessChen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017impaired insulin tolerance compared to dexamethasone-treated wild-
type mice (Fig. 1, D and E). These results demonstrated that a lack of
Angptl4 prevented the whole-body insulin insensitivity induced by
glucocorticoid exposure.
We next performed PTTs to assess the effect of glucocorticoids on
hepatic gluconeogenesis. After pyruvate injection, dexamethasone-
treated wild-typemice had higher plasma glucose concentrations than
control mice over the course of the experiment (Fig. 1, F and G). In
contrast, plasma glucose concentrations in PBS- and dexamethasone-
treated Angptl4−/−mice were similar after pyruvate injection (Fig. 1, F
and G). These results demonstrated that the ability of glucocorticoids
to stimulate hepatic gluconeogenesis was attenuated in mice lacking
Angptl4.
To identify the organ that contributes to the insulin sensitivity
observed upon Angptl4 depletion, we monitored the activity of Akt in
epididymalWAT (eWAT), liver, and gastrocnemiusmuscle after 10min
of insulin treatment in control and dexamethasone-treated wild-type
and Angptl4−/− mice. Akt is phosphorylated at Ser473 and Thr308 upon
insulin treatment (17), and we monitored phosphorylation of Thr308
as an indicator forAkt activation. Insulin treatment caused an increase
in the phosphorylation ofAkt in the liver and gastrocnemiusmuscle of
control wild-type mice but not in those of dexamethasone-treated
wild-type mice (Fig. 2, A and B). These results demonstrated that
dexamethasone treatment prevented insulin activation of Akt in these
two tissues. In contrast, insulin treatment increased the phosphorylation0
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Fig. 1. Dexamethasone-induced glucose, insulin, and pyruvate intolerance were improved in Angptl4−/−
mice. Wild-type (WT) and Angptl4−/− mice were treated with phosphate-buffered saline (PBS) or dexamethasone
(Dex). (A) GTT was performed after 16 hours of fasting. (B) Relative area under curve (AUC) for GTT results (relative
to PBS-treated WT mice) is shown. Error bars represent SEM. n = 5 to 7 mice per group. *P < 0.05. (C) Plasma insulin
concentrations were measured before glucose injection (0 time point), and 15 and 30 min after glucose injection.
Error bars represent SEM. n = 5 to 7 mice per group. * indicates significant (P < 0.05) effect of dexamethasone
(compared to PBS) at the given time point, ** indicates significant difference (P < 0.05) between WT dexamethasone
and Angptl4−/− dexamethasone at the given time point, and *** indicates significant (P < 0.05) difference between
time points. (D) ITT was performed, and results are displayed as percentage of initial plasma glucose concentrations
at different time points. (E) Relative AUC for ITT results (relative to PBS-treated WT mice) is shown. Error bars repre-sent SEM. n = 5 to 7 mice per group. *P < 0.05. (F) Pyruvate tolerance test (PTT) was performed. (G) Relative AUC for PTT results (relative to PBS-treated WT mice) is shown.
Error bars represent SEM. n = 3 to 5 mice per group. *P < 0.05.2 of 11
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they were untreated or given dexamethasone (Fig. 2, A and B). Thus, in
the absence of Angptl4, insulin still activated Akt in the liver and gas-
trocnemius muscle even in the presence of dexamethasone. For eWAT,
insulin treatment increased the phosphorylation of Akt in both control
anddexamethasone-treatedwild-typeorAngptl4−/−mice (Fig. 2C).These
results demonstrated that dexamethasone treatment induced insulin
resistance in the liver and skeletal muscle of wild-typemice, an effect that
was substantially reversed inAngptl4−/−mice. In contrast, dexamethasone
treatment in eWAT had more complex effects on insulin signaling be-
cause insulin-stimulated Akt activation was present both under basal
conditions and upon dexamethasone treatment. However, maximal
Akt activation was somewhat reduced.
Metabolomic profiling showed alterations of lipid
metabolites in the gastrocnemius muscle and liver in control
and dexamethasone-treated wild-type and Angptl4−/− mice
We hypothesized that Angptl4 was involved in glucocorticoid-induced
insulin resistance bymobilizing fatty acids fromWATwhich were then
converted in the liver and skeletalmuscle tometabolites thatmodulatedChen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017insulin action. To test this model, we performed single reaction
monitoring (SRM)–based targeted metabolomic analysis to quantify
the concentrations of about 150 common lipidmetabolites (data file S1).
We focused on the gastrocnemius muscle and liver because they be-
came insulin-resistant upon dexamethasone treatment in our experimen-
tal system (Fig. 2, A and B). We found that dexamethasone treatment
significantly increased the amounts of 11 metabolites and decreased
the amounts of 48 metabolites in the liver of wild-type mice (Fig. 3A
and data file S1). Surprisingly, none of the lipid species identified in
muscle tissues were significantly increased after dexamethasone treat-
ment in wild-type mice, although nine metabolite species were reduced
(data file S1); none of these nine metabolites had previously been asso-
ciated with the development of insulin resistance.
Six of the 11metabolites thatwere increased inwild-typemouse liver
by dexamethasone treatment were significantly lower in dexamethasone-
treated Angptl4−/−mice. These were C18:0 ceramide, C16:0 sphingosine
phosphate (S1P),C16:0/C18:1/C16:0 triacylglycerol (TAG),C18:0/C18:1/
C18:0 TAG, C18:0/C18:1 diacylglycerol (DAG), and C16:0/C18:1
phosphatidylethanolamine (PE) (Fig. 3B). Although the amounts of
ceramides, DAG (18, 19), and S1P (20, 21) have been correlated with o
n
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 the development of insulin resistance,
only ceramides have been linked to the
glucocorticoid-induced modulation of
insulin sensitivity (11).
We performed liver histology to visu-
alize the morphological changes of hepa-
tocytes after dexamethasone treatment.
For wild-type mice, dexamethasone treat-
ment increased the size of hepatocytes, in
which the unstained areas were likely due
to the accumulation of triglycerides (fig.
S2A). Dexamethasone treatment also
increased the size of hepatocytes in
Angptl4−/− mice (fig. S2A). However, he-
patocytes in dexamethasone-treated
Angptl4−/−mice were smaller than those in
dexamethasone-treated wild-type mice
(fig. S2A). This finding agrees with re-
duced induction of triglyceride concen-
trations in Angptl4−/− mouse liver (Fig. 3,
A and B). We did not observe statistically
significant differences in eWATweight be-
tween control and dexamethasone-treated
wild-type and Angptl4−/− mice (fig. S2B).
This result is likely due to the concomitant
stimulation of triglyceride synthesis and li-
polysis by dexamethasone inWATs (13, 22).
Activation of the hepatic ceramide
synthetic program was attenuated
in Angptl4−/− mice
Distinct ceramide species, which are
defined by their fatty acyl chain length,
can exert specific biological functions
(23, 24). Therefore, we expanded our ini-
tial SRM-based targeted metabolomic
analysis by analyzing multiple ceramide
species to determine whether their
abundance in the liver was modulated0
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Fig. 2. Dexamethasone-induced insulin resistance in
the liver and gastrocnemius muscle was improved in
Angptl4−/− mice. WT and Angptl4−/− mice were treated
with PBS or dexamethasone and then vehicle or insulin
(Ins). (A to C) The amounts of total Akt and phosphorylated
Akt (p-Akt) were measured in the liver (A), gastrocnemius
muscle (B), and eWAT (C). Gapdh was used as an internal
control. The intensity of bands was normalized to those
for Gapdh. The relative ratio of p-Akt to Akt represents the
Akt activity. Error bars represent SEM. n = 3 to 4 mice per
group. *P < 0.05.3 of 11
SC I ENCE S I GNAL ING | R E S EARCH ART I C L E
 o
n
 July 25, 2017
http://stke.sciencem
ag.org/
D
ow
nloaded from
 by dexamethasone treatment. Sixteen of the ceramide species were
similar in abundance between control wild-type andAngptl4−/−mice
(Fig. 4A). However, dexamethasone treatment markedly increased
the amounts of a subset of ceramide species, including C16:0,
C18:0, C20:0, C20:1, C20:2, C22:1, C22:2, C24:2, and C26:0 cera-
mides in wild-type mouse liver (Fig. 4A). These ceramide species
were lower in abundance in the livers of dexamethasone-treated
Angptl4−/− mice (Fig. 4A). C24:1 ceramides were the only species
that were reduced by dexamethasone treatment in the livers of
wild-type mice (Fig. 4A), a decrease that was more pronounced in
the livers of dexamethasone-treated Angptl4−/− mice.
The simplestmodel to explain the overall reduction of ceramide spe-
cies in the livers of dexamethasone-treated Angptl4−/−mice is that the
stimulation of lipolysis by dexamethasone in WAT is diminished in
Angptl4−/− mice, which then decreases the availability of palmitate
for hepatic ceramide synthesis.We found that dexamethasone treatment
for 7 days increased plasma palmitate (C16:0 free fatty acid) concen-
trations by about 50% in wild-type mice (Fig. 4B). In dexamethasone-
treated Angptl4−/− mice, plasma palmitate concentrations were 27%
lower than those of dexamethasone-treated wild-type mice, although
this difference was not statistically significant (Fig. 4B). Plasma stearic
acid (C18:0 free fatty acid) concentrations were also augmented by
dexamethasone treatment in wild-type mice, and this induction was
significantly reduced in dexamethasone-treatedAngptl4−/−mice (Fig. 4B).
However, dexamethasone treatment did not affect the concentrations
of C18:1, C20:4, and C22:6 free fatty acids in wild-type mice (Fig. 4B).
Plasma C16:0, C18:0, and C20:4 free fatty acid concentrations were
either significantly or trending higher in control Angptl4−/−mice than
those in control wild-typemice (Fig. 4B). These results likely reflect the
higher activity of LPL in the plasma of Angptl4−/− mice (25). We also
measured the plasma concentrations of representative ceramide species
and found that the increase in the amounts of C16:0, C18:0, and C20:4Chen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017ceramides in wild-typemice induced by dexamethasonewas attenuated
in Angptl4−/− mice (Fig. 4C).
Although dexamethasone treatment increased fatty acid flux
from WAT to the liver, only 11 lipid species were increased by glu-
cocorticoids in the livers of wild-type mice. This observation sug-
gested that, in addition to increasing the availability of hepatic
fatty acids, dexamethasone may stimulate specific metabolic path-
ways that regulate ceramide synthesis. Therefore, we tested this idea
by analyzing the expression of genes encoding enzymes involved in
ceramide synthesis. In agreement with previous observations, we
found that Spt2, Cers3, Cers4, Cers5, and Cers6, which are genes en-
coding enzymes in the de novo ceramide synthetic pathway, were all
induced by dexamethasone treatment (Fig. 4D and fig. S1) (11). The ex-
pression of Smpd1, which encodes an enzyme that converts sphingo-
myelins to ceramides (Fig. 4E), was also augmented by dexamethasone
(Fig. 4D and fig. S1). Dexamethasone also increased the expression of
Sgms1, which encodes an enzyme that converts ceramides to sphin-
gomyelins (Fig. 4E). Counterintuitively, the induction of Sgms1 and
Smpd1 by dexamethasone promotes the bidirectional interconversion
of ceramides and sphingomyelins, reminiscent of the effect of glu-
cocorticoid in both promoting hepatic glycogen synthesis and glu-
coneogenesis (2, 26). Because we observed decreased levels of
sphingomyelins (C16:0 and C18:0) upon dexamethasone treatment
(Fig. 3A), we postulated that induction of Smpd1 likely dominates over
the Sgms1 induction by dexamethasone. Finally, the stimulation of
Sphk1 expression, a gene that encodes an enzyme that converts sphin-
gosine to S1P (Fig. 4E), likely explains the decreased sphingosine and
increased S1P amounts in the livers of dexamethasone-treated wild-type
mice (Fig. 3A).
InAngptl4−/−mice, the ability of dexamethasone to augment the ex-
pression ofCers3,Cers4,Cers5,Cers6, and Sphk1was impaired, whereas
the induction of Spt2 and Smpd1 by dexamethasone was not affected0
2
4
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C16:0 S1P
B
WT-PBS
WT-Dex
Angptl4    - PBS–/–
–/–Angptl4    - Dex
0
1
2
3
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C18:0 Ceramide
0
2
4
6
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C18:0/C18:1 DAG
0
1
2
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C16:0/C18:1 PE
0
5
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C16:0/C18:1/C16:0 
TAG
0
2
4
PBS Dex PBS Dex
R
el
at
iv
e 
am
ou
nt
s
C18:0/C18:1/C18:0 
TAG
*
*
*
*
* * * *
*
* *
*
Lower amounts of metabolite Higher amounts of metabolite
Sp
hi
ng
os
in
e
C1
8:
1 
NA
E
C1
6:
0 
M
AG
C1
8:
0p
 M
AG
p
C1
6:
0e
/C
2:
0 
M
AG
e
C1
8:
0 
M
AG
C2
0:
4 
M
AG
C1
8:
0p
/C
2:
0 
M
AG
p
C1
8:
0e
/C
2:
0 
M
AG
e
C2
2:
6 
M
AG
C1
8:
1 
LP
E
C1
6:
0e
 L
PC
e
C1
6:
0 
LP
C
C1
6:
0 
LP
S
C1
8:
0e
 L
PG
e
C2
0:
4 
LP
E
C1
8:
0p
 L
PC
p
C1
8:
0e
 L
PC
e
C1
8:
1 
LP
C
C1
8:
1 
LP
S
C2
0:
4e
 L
PC
e
C2
0:
4 
LP
C
C2
0:
4 
LP
S
C2
0:
1 
LP
C
C1
8:
0p
 L
PC
p
C2
0:
0 
LP
C
C1
8:
0 
ce
ra
m
id
e
C1
6:
0/
C2
0:
4 
DA
G
C1
8:
0/
C1
8:
1 
DA
G
C1
6:
0 
SM
C1
6:
0/
C1
8:
1 
PE
C1
8:
0 
SM
C1
8:
0/
C1
8:
1 
PE
C1
6:
0e
/C
18
:1
 P
Ce
C1
6:
0e
/C
18
:1
 P
Se
C1
6:
0/
C1
8:
1 
PC
C1
6:
0e
/C
20
:4
 P
Ce
C1
6:
0/
C2
0:
4 
PC
C1
6:
0/
C2
0:
4 
PS
C1
8:
0p
/C
20
:4
 P
Cp
C1
8:
0p
/C
20
:4
 P
Sp
C1
8:
0/
C2
0:
4 
PG
C1
8:
0/
C2
0:
4 
PS
C1
6:
0/
C1
8:
1/
C1
6:
0 
TA
G
C1
6:
0/
C2
0:
4/
C1
6:
0 
TA
G
C1
8:
0/
C1
8:
1/
C1
8:
0 
TA
G
C1
8:
0/
C1
8:
0/
C1
8:
0 
TA
G
C1
6:
0 
FF
A
C1
8:
1 
FF
A
C1
8:
0 
FF
A
C2
0:
4 
FF
A
C2
2:
6 
FF
A
C1
6:
0 
S1
P
C1
8:
1 
LP
A
C1
6:
0/
C2
0:
4 
PA
C1
8:
0e
/C
20
:4
 P
A
e
C1
8:
0e
/C
18
:1
 P
Ie
C1
6:
0/
C2
0:
4 
PI
C1
8:
0/
C1
8:
1 
PI
A
WT    WT    Angptl4–/–Angptl4–/–Angptl4–/–Angptl4–/–Angptl4–/–Angptl4–/– WT    WT    WT    WT    
Fig. 3. Metabolomics analysis in the liver and gastrocnemius muscle of control and dexamethasone-treated WT and Angptl4−/− mice. WT and Angptl4−/− mice
were treated with PBS or dexamethasone for 7 days. (A) Metabolomics analysis was performed on hepatic lipids. The heat map shows metabolites that are significantly
altered in content (P < 0.05) upon dexamethasone treatment in the livers of WT mice. The relative content was displayed in the heat map compared to the WT PBS group.
Red shading on the heat map indicates higher relative amounts, and green shading represents lower relative amounts. (B) Six lipid metabolites that were significantly
increased in abundance in dexamethasone-treated WT mice liver but not in dexamethasone-treated Angptl4−/− mice are shown. Error bars represent SEM. n = 4 mice per
group. *P < 0.05.4 of 11
SC I ENCE S I GNAL ING | R E S EARCH ART I C L E
 o
n
 July 25, 2017
http://stke.sciencem
ag.org/
D
ow
nloaded from
 0
0.5
1
1.5
2
C16:0 
FFA
C18:0 
FFA
C18:1 
FFA
C20:4 
FFA
DHA
R
el
at
iv
e 
ra
tio
co
m
pa
re
 to
 W
T 
PB
S WT - PBS
WT - Dex
0
0.5
1
1.5
2
2.5
3
C16:0 C18:0 C18:1 C20:0 C20:1 C20:2 C20:4 C22:0 C22:1 C22:2 C22:4 C24:0 C24:1 C24:2 C26:0 C26:1
R
el
at
iv
e 
ra
tio
co
m
pa
re
 to
 W
T 
PB
S
Ceramide
WT - PBS
WT - Dex
*
*
*
*
*
* *
Lower expression Higher expression
******** *
WT - PBS
WT - Dex
Angptl4    - PBS–/–
Angptl4    - Dex–/–
Angptl4     - PBS–/–
Angptl4     - Dex–/–
D
E
Ceramide 
Dihydroceramide
SphingosineSphingomyelin
Ceramide-1-phosphate Glucosylceramide
S1P
Des1
Cers3-6
Asah1
Sphk1 Sgpp1
Sgms1
Smpd1
GbaCerk
3-keto-dihydrosphingosine
Spt2
Palmitoyl-CoA
Sphinganine 
Cers3-6
Ugcg
* *
B
*
*
*
*
*
Sp
t1
Sp
t2
Ce
rs
2
Ce
rs
3
Ce
rs
4
Ce
rs
5
Ce
rs
6
D
es
1
Sg
m
s1
Sm
pd
1
Ce
rk
Sp
hk
1
Sg
pp
1
As
ah
1
Ug
cg
G
ba
0
1
2
3
C16:0 C18:0 C18:1 C20:4
R
el
at
iv
e 
ra
tio
co
m
pa
re
 to
 W
T 
PB
S WT - PBS
WT - Dex
C
*
* *
*
*
*
*
*
F
Cers6
-Actin
WT                         Angptl4–/–
PBS         Dex            PBS          Dex
Cers5
0
0.5
1
1.5
2
PBS Dex PBS Dex
Ce
rs
5/
-
Ac
tin
0
0.5
1
1.5
2
2.5
3
PBS Dex PBS Dex
P = 0.07
*
*
WT     Angptl4–/–
**
Ceramide
WT     
A
Angptl4     - PBS–/–
Angptl4     - Dex–/–
Angptl4     - PBS–/–
Angptl4     - Dex–/–
Ce
rs
6/
-
Ac
tin
Angptl4–/–
Fig. 4. Dexamethasone-activated hepatic ceramide synthetic program was attenuated in Angptl4−/− mice. WT and Angptl4−/− mice were treated with PBS or
dexamethasone for 7 days. (A to C) The concentrations of 16 different ceramide species in the liver (A), 5 different free fatty acids (FFAs) in plasma (B), and 4 ceramide
species in plasma (C) of these mice were measured. n = 4 mice per group. (D) The expression of genes encoding enzymes involved in ceramide production was
monitored using quantitative polymerase chain reaction (qPCR). The heat map shows the relative expression compared to that in the WT PBS group. Red shading
on the heat map indicates higher expression, and green shading represents lower expression. The changes in fold induction are shown in fig. S1. n = 16 mice per group.
(E) Schematic representation of ceramide synthesis pathways. The genes and metabolites that were induced by dexamethasone in WT mice liver are shown in red. The
metabolites that were reduced by dexamethasone are shown in green. (F) The abundance of Cers5 and Cers6 proteins was monitored using Western blot. The bar
graph represents the average intensity of bands normalized to those for Gapdh. Error bars represent SEM. n = 3 to 4 mice per group. *P < 0.05.Chen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017 5 of 11
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 (Fig. 4D). The decreased expression of Sphk1 could explain the reduced
S1P amounts in the livers of dexamethasone-treated Angptl4−/− mice
compared to dexamethasone-treated wild-type mice (Fig. 3, A and B).
Overall, these results suggested that the reduction in ceramide production
in the livers of Angptl4−/− mice was due to both diminished substrate
availability and impairment in the induction of ceramide synthetic en-
zymes by dexamethasone (Fig. 4E). To confirm that the gene expression
changes were reflected at the protein level, we performed immuno-
blotting for Cers5 and Cers6 as representative enzymes in ceramide
synthesis. The abundance of these two proteins was increased by dexa-
methasone in the livers of wild-typemice but not inAngptl4−/−mice (Fig.
4F). Overall, these gene expression analyses agreed with themetabolomic
results, which demonstrated complex effects of dexamethasone on
ceramide metabolism (Fig. 4E).
The activation of downstream signaling effectors by ceramides
was impaired in dexamethasone-treated Angptl4−/− mice
Protein phosphatase 2A (PP2A) and protein kinase Cz (PKCz) act
downstream of ceramide-initiated signaling (27, 28). To estimate
the PP2A activity, we measured dephosphorylation of threonine-
phosphopeptides using immunoprecipitates of PP2A from liver lysates.
We found that dexamethasone treatment increased PP2Aactivity in theChen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017livers of wild-type mice (≈1.8-fold), an effect that was reduced in those
of Angptl4−/− mice (Fig. 5A). We found that autophosphorylation of
Thr560 of PKCz, which is required for PKCz activation (29), was
increased by dexamethasone treatment in the livers of wild-type mice,
an effect that was reduced in those of Angptl4−/−mice (Fig. 5B). These
results validated the concept that dexamethasone treatment stimulates
ceramide-initiated signaling in the liver, which is impaired in the ab-
sence of Angptl4.
To test whether PP2A is involved in glucose intolerance induced by
glucocorticoids, wild-type andAngptl4−/−mice were infected with ad-
enovirus expressing scrambled small hairpin RNA (shRNA) (control)
or shRNA targeting Ppp2ca, which encodes a PP2A catalytic subunit.
Western blots confirmed a significant reduction in the protein abun-
dance of the PP2A catalytic subunit by Ppp2ca shRNA in mouse liver
(fig. S3A). Moreover, PP2A activity was about 60% lower in the livers
ofmice expressing Ppp2ca shRNA than that of control mice (fig. S3B).
IPGTTs revealed that reducing hepatic PP2A activity improved glu-
cose tolerance in dexamethasone-treated wild-type mice (Fig. 5C).
Dexamethasone-treated Angptl4−/− mice were more glucose-tolerant
thandexamethasone-treatedwild-typemice (Fig. 5C). Reducing hepatic
Ppp2ca expression in dexamethasone-treated Angptl4−/− mice further
improved glucose tolerance (Fig. 5C).0
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 To evaluate the role of PKCz in glucocorticoid-induced glucose in-
tolerance, wild-type andAngptl4−/−micewere injectedwith orwithout
2-acetyl-1,3-cyclopentanedione (ACPD), an inhibitor of atypical
PKC, PKCz, and PKCi (30, 31) for the final 4 days of the 7-day dexa-
methasone course, which reduced PKCz activity (fig. S3C). IPGTTs
showed that ACPD treatment significantly improved glucose toler-
ance in dexamethasone-treated wild-type but not in Angptl4−/− mice
(Fig. 5D). Overall, these results suggested that both PP2A and PKCz
are involved in dexamethasone-induced glucose intolerance.
The inhibition of ceramide synthesis by myriocin reduces
dexamethasone-induced insulin resistance in wild-type but
not in Angptl4−/− mice
Inhibiting ceramide synthesis by the Spt1 and Spt2 inhibitor myriocin
(32) reduces dexamethasone-induced insulin resistance (11). If the
major role for Angptl4 in dexamethasone-induced insulin resistance
is to increase hepatic ceramideproduction,wehypothesized that blocking
ceramide synthesis would improve insulin sensitivity in dexamethasone-
treated wild-type but not in dexamethasone-treated Angptl4−/− mice.
Consistent with our model, we found that treatment with the ceramide
synthase inhibitor myriocin attenuated dexamethasone-induced glucose
intolerance in wild-type mice but not in Angptl4−/− mice (Fig. 6A).
We also monitored the activity of PKCz to validate our hypothesis
that the effect ofmyriocin wasmediated through ceramide generation.
We focused onPKCz because reducingPKCz activity, similar tomyriocin
treatment, did not further improved glucose tolerance in dexamethasone-
treated Angptl4−/−mice (Fig. 5D). Myriocin treatment markedly de-
creased the phosphorylation of PKCz in dexamethasone-treatedChen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017wild-type mice (Fig. 6B). These results
suggested that myriocin treatment re-
duced the ceramide-initiated signaling
that was induced by dexamethasone.
In contrast, in dexamethasone-treated
Angptl4−/− mice, myriocin treatment
did not affect PKCz phosphorylation
(Fig. 6B). These results agreed with
the lack of effect of myriocin on glucose
tolerance in dexamethasone-treated
Angptl4−/− mice (Fig. 6B).DISCUSSION
The molecular mechanisms underlying
the antagonistic effect of glucocorticoids
on whole-body insulin sensitivity are not
clear. Our present studies demonstrated
that Angptl4, a primary target gene of
glucocorticoid receptor in hepatocytes
and adipocytes (12), plays a key role in
glucocorticoid-induced insulin resistance.
We have previously shown that Angptl4
is required for glucocorticoid-induced
WAT lipolysis and that purified Angptl4
proteins can directly enhance lipolysis in
primary adipocytes (14). Here, we showed
thatAngptl4was required for glucocorticoid-
induced ceramide production and ceramide-
initiated signaling in the liver. On the basis
of these results, we propose that Angptl4participates in glucocorticoid-induced insulin resistance by promoting
lipolysis in WAT, which mobilizes fatty acids that are taken up by the
liver for ceramide production (Fig. 7). In addition to promoting adi-
pocyte lipolysis, Angptl4 also inhibits extracellular LPL (15, 16). Our
present studies mainly focused on the lipolytic effect of Angptl4 in
glucocorticoid-induced insulin resistance. However, we cannot exclude
a role for the inhibitory effect of Angptl4 on LPL in regulating insulin
sensitivity. Reducing LPL activity may lead to hypertriglyceridemia,
which could also contribute to insulin resistance.
The simplest model for Angptl4 action in glucocorticoid-induced
insulin resistance is that enhancing WAT lipolysis provides the pre-
cursors, such as palmitate, for hepatic ceramide production. On the
basis of our results, Angptl4 action also provided signals needed for
glucocorticoids to activate ceramide synthetic pathways in the liver,
because without Angptl4, the ability of dexamethasone to stimulate
specific ceramide synthetic genes was attenuated (Fig. 7). Gluco-
corticoid treatment increases the expression of several genes involved
in ceramide synthesis in the liver (11) through unknownmechanisms.
Chromatin immunoprecipitation sequencing analysis in mouse liver
has identified glucocorticoid receptor binding sites in or nearby genomic
regions of several ceramide synthetic genes, such as Cers6, Cers3, and
Spt2 (33). However, whether these genes are indeed glucocorticoid re-
ceptor primary target genes would require further study. In addition to
the direct activation of ceramide synthetic genes by glucocorticoid re-
ceptor, another potential mechanism is that the fatty acids generated
by Angptl4-induced lipolysis in WAT provide the signals to act with
glucocorticoids to regulate ceramide synthetic genes. Saturated fatty
acids activate nuclear factor kB (NFkB) to stimulate ceramide synthetic0
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 genes in the liver (23, 34), although the glucocorticoid receptor antag-
onizes NFkB responses (35, 36). Alternatively, fatty acids can serve as
ligands for peroxisome proliferator–activated receptor a and g (PPARa
and PPARg, respectively) (37, 38). PPARa increases ceramide produc-
tion in the heart (39), skin (40), and trophoblasts (41), whereas PPARg
promotes ceramide synthesis in keratinocytes (42).
It was intriguing that our results showed an increase in various cer-
amide species by dexamethasone in the liver and that dexamethasone
treatment increased the expression of at least four ceramide synthases
(Cers3-6). Each ceramide synthase is responsible for synthesizing different
species of ceramides, and various studies indicate that different ceramide
species exert distinct physiological functions (23, 24). For example, the de-
letion ofCers6 gene in the liver, which results in decreasedC16:0 ceramide
concentrations, protects mice from high-fat diet–induced insulin
resistance (43). In contrast, haploinsufficiencyofCers2 gene inmice results
in the development of insulin resistance (44). In the livers of these Cers2
heterozygousmice, the amounts ofC16:0 ceramides and the abundance of
Cers5 and Cers6, two proteins that are responsible for the production of
C16:0 ceramides, are increased. Furthermore, increasing acid ceramidase
expression in the liver decreases the concentrations of C16:0 and C18:0
ceramides that are correlated to the reduction in both PKCz activity
and the development of insulin resistance (31). Overall, these results
suggest that C16:0 ceramides suppress insulin sensitivity. On the basis
of our results, the abundance of Cers5 and Cers6 proteins and C16:0
ceramides in the liver was induced by dexamethasone. Thus, Cers5
and/or Cers6 could potentially act downstream of Angptl4 to confer
dexamethasone-induced insulin resistance. Moreover, in addition to
ceramides, our metabolomics studies identified dexamethasone-
induced increases in other lipid metabolites, including C18:0/18:1 DAG
and C16:0 S1P, which are increased in insulin resistance. DAG amounts
in the liver are associated with the development of insulin resistanceChen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017(18, 19), and the amounts of C18:0/18:1 DAG are positively correlated
with homeostatic model assessment–insulin resistance (45). In con-
trast, S1P inhibits insulin action through S1P receptor 2 (S1P2) in the liver
(20, 21). Note that our results have not identified the specific ceramide
species and/or metabolites involved in glucocorticoid-induced insulin
resistance. The potential role of Cers3-6 and Sphk1 on glucocorticoid-
induced insulin resistance remains to be established.
Although PKCz and PP2A are downstream of ceramides, their
roles in glucocorticoid-induced insulin resistance have not been
examined. Here, we showed that both were involved in glucose in-
tolerance induced by dexamethasone treatment. Reducing PP2A
abundance but not PKCz activity further improved glucose tolerance
in dexamethasone-treated Angptl4−/− mice, suggesting that the stim-
ulation of PKCz in the liver by glucocorticoids mainly required
Angptl4, whereas there are other glucocorticoid-regulated mecha-
nisms that can activate PP2A. It is unclear whether PP2A and PKCz
act in the same or the parallel pathway to modulate insulin actions.
The increase in ceramide concentrations in the liver explains the
role of Angptl4 in glucocorticoid-induced hepatic insulin resistance.
However, insulin response in the gastrocnemius muscle was also im-
proved in Angptl4−/− mice. It is surprising that in the gastrocnemius
muscle, only nine metabolites were affected by dexamethasone treat-
ment, and none of them have been previously linked to insulin sensi-
tivity. It is possible that the metabolites modulated by dexamethasone
treatment to induce insulin resistance in the gastrocnemius muscle
were not in the list of target metabolomics experiments we conducted.
Notably, ceramides are mainly associated with very-low-density lipo-
protein (VLDL) in plasma (46), and plasma ceramide concentrations
have beennegatively associatedwith insulin sensitivity (47, 48). There-
fore, it is also possible that ceramides produced in the liver are mobi-
lized to the gastrocnemius muscle to inhibit insulin action (49). This
model is somewhat supported by our observation that plasma cer-
amide concentrations were augmented by dexamethasone in wild-
type but not in Angptl4−/− mice (Fig. 4C).
High-fat diet feeding causes inflammation in WAT. Secretion of
interleukin-6 from macrophages in WAT increases, which promotes
WATlipolysis and in turn induceshepatic insulin resistance (50).Although
the induction of WAT lipolysis is also involved in the glucocorticoid-
induced development of insulin resistance, glucocorticoid exposure ac-
tually suppresses, rather than promotes, inflammation in WAT (51).
Thus, the glucocorticoid-induced increase inAngptl4 expression, rather
than cytokine production, may be the key step in glucocorticoid-induced
insulin resistance.However, Angptl4 is unlikely to be the onlymediator
of the suppressive effect of glucocorticoids on insulin action, and a
network of glucocorticoid primary target genes are likely needed to
exert the effect of glucocorticoids on whole-body insulin sensitivity.
Regardless, our studies suggest that Angptl4 plays a critical role in
triggering interorgan communication between theWAT and the liver,
leading to the suppression of insulin action. Overall, these results fill
an important gap in our understanding of the metabolic functions of
glucocorticoid. Furthermore, targeting Angptl4 may be a promising
strategy to dissociate the beneficial anti-inflammatory effects of gluco-
corticoids from adverse effects such as insulin resistance.METHODS
Animals
Angptl4−/− mice were provided by the laboratories of A. Nagy
(Samuel Lunenfeld Research Institute, Mount Sinai Hospital) andGlucocorticoidsAngptl4
TG
Glycerol + FA
Palmitoyl-CoA 
    + 
Serine
Cers3-6
Ceramides
PP2A PKC
Akt
White adipose tissues
Liver
Spt2
Fig. 7. The proposed model for the role of Angptl4 in glucocorticoid-induced
hepatic insulin resistance. Glucocorticoid activates the expression of Angptl4, which
promotes lipolysis in WAT. Fatty acids (FAs) generated from lipolysis of triglycerides
(TGs) serve as both precursors for ceramide synthesis (such as palmitate) and also
signals to act with glucocorticoids to increase the expression of Cers3, Cers4, Cers5,
and Cers6. Spt1 and Spt2 expression is also induced by glucocorticoids, though this
induction does not require Angptl4. Ceramides subsequently activate PKCz and
PP2A, which inhibit Akt and result in insulin resistance.8 of 11
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 J. Gordon (Washington University) (52). Angptl4−/− mice were gener-
ated on a mixed B6:129 Sv background. Angptl4+/+ mice (wild-type
mice) were the littermates of Angptl4−/− mice. Male (7 to 12 weeks
old) mice were used in this study. The genotyping method was per-
formed as previously described (52). To test insulin signaling, we
injected the mice with insulin (1 U per body weight) for 10 min,
and Western blot analysis was performed on various tissues. The Office
of Laboratory Animal Care at the University of California, Berkeley,
approved all the animal experiments (AUP-2014-08-6617).
Drug administration
Male (7 to 12 weeks old) Angptl4+/+ (wild-type) and Angptl4−/−
mice were treated with dexamethasone (~0.42 mg/kg) for 7 days
through drinking water. Water-soluble dexamethasone (Sigma,
D2915) was dissolved in PBS (25 mg/ml). Notably, water-soluble
dexamethasone contains 65 mg of dexamethasone per gram of pow-
der. We prepared drinking water that contains 0.0025 g of dexa-
methasone per liter and based on our estimate that a 30-g mouse
drinks about 3.5 to 5 ml of water per day. In myriocin experiments,
myriocin (0.5 mg/kg body weight) was dissolved in PBS and was
injected intraperitoneally to mice on the last 4 days of dexametha-
sone treatment. For ACPD (Sigma, A155) treatment, mice were
injected subcutaneously with ACPD (10 mg/kg) dissolved in PBS
for 4 days.
IPGTT, ITT, and PTT
Mice were fasted for 6 or 16 hours for GTT and PTT. Mice were
injected with glucose (1 g/kg body weight), insulin (1 U/kg body
weight, Sigma, I0516-5ML), or sodium pyruvate (1 mg/kg body
weight, Spectrum Chemical, SO193) intraperitoneally. Blood samples
(one drop from tail vein) were obtained at the 0-, 30-, 60-, 90-, and
120-min time points to measure glucose levels using CONTOUR
Blood Glucose Monitoring System (Contour, Bayer). Blood was also
collected during different time points of GTT for measuring plasma
insulin concentrations.
Lipidomic profiling
Liver tissues and gastrocnemiusmuscle tissueswere used for lipidomic
profiling. Lipidmetabolites were extracted in 4ml of a 2:1:1mixture of
chloroform/methanol/Tris buffer with inclusion of internal standards
C12:0 dodecylglycerol (10 nmol) and pentadecanoic acid (10 nmol).
Organic and aqueous layers were separated by centrifugation at 1000g
for 5 min, and the organic layer was collected, dried down under N2,
and dissolved in 120 ml of chloroform, of which 10 ml was analyzed by
both SRM-based liquid chromatography–tandem mass spectrometry
(LC-MS/MS) or untargeted LC-MS. LC separation was achieved with a
Luna reverse-phase C5 column (50 mm× 4.6 mmwith 5-mm-diameter
particles, Phenomenex). Mobile phase A was composed of a 95:5 ratio
of water/methanol, and mobile phase B consisted of a 60:35:5 ratio of
2-propanol/methanol/and water. Solvent modifiers (0.1% formic acid
with 5 mM ammonium formate and 0.1% ammonium hydroxide)
were used to assist ion formation and to improve the LC resolution
in both positive and negative ionization modes, respectively. The flow
rate for each run started at 0.1 ml/min for 5 min to alleviate backpres-
sure associated with injecting chloroform. The gradient started at 0%
B and increased linearly to 100% B over the course of 45 min with a
flow rate of 0.4ml/min, followed by an isocratic gradient of 100%B for
17min at 0.5ml/min before equilibrating for 8min at 0%Bwith a flow
rate of 0.5 ml/min.Chen et al., Sci. Signal. 10, eaai7905 (2017) 25 July 2017MS analysis was performed with an electrospray ionization source
on an Agilent 6430 QQQ LC-MS/MS. The capillary voltage was set to
3.0 kV, and the fragmentor voltage was set to 100 V. The drying gas
temperature was 350°C, the drying gas flow rate was 10 liters/min, and
the nebulizer pressure was 35 psi. Representative metabolites were
quantified by SRM of the transition from precursor to product ions
at associated collision energies. Data were normalized to the internal
standards and also external standard curves of metabolite classes
against the internal standards, and concentrations were calculated as
relativemetabolite concentrations compared to controls. These internal
standards were added alongside dodecylglycerol and pentadecanoic
acid in the 2:1:1 chloroform/methanol/Tris buffer mixture.
Western blot
Theprotein concentrationsof samplesweremeasuredusingbicinchoninic
acid (BCA) protein assay (Thermo Scientific, 23228). Proteins (~30 mg)
were mixed with 1X NuPAGE LDS Sample Buffer (ThermoFisher,
NP0007) and 1X NuPAGE Sample Reducing Agent (ThermoFisher,
NP0009), boiled for 5 min before applying to SDS–polyacrylamide
gel electrophoresis. The following are the antibodies we used in this
study: anti-Gapdh (Santa Cruz, sc-25778), anti-Akt (Cell Signaling,
9272s), anti–phospho-Akt (Cell Signaling, 9275s), anti-Cers5 (Life
Technologies, PA-520570), anti-Cers6 (Santa Cruz, sc-100554),
anti–b-actin (Santa Cruz, sc-47778), anti-PKCz (Santa Cruz, sc-216),
anti–phospho-PKCz (T410, Cell Signaling, 2060S), anti-Ppp2ca (Cell
Signaling, 2041S). The intensity of the bands was quantified using
ImageJ software (National Institutes of Health) and normalized to
Gapdh or b-actin.
PP2A activity assay
The PP2A activity in the liver lysate was detected using PP2A Im-
munoprecipitation Phosphatase Assay kit (Millipore, 17-313FR)
following the manufacturer’s protocol.
Real-time qPCR
TotalRNAwas isolated fromliver tissuesusingTRIzol reagent (Invitrogen,
15596018). Reverse transcription was performed as follows: 0.5 mg of
total RNA, 4 ml of 2.5 mM dNTP, and 2 ml of 15 mM random primers
(New England Biolabs, S1254S) were mixed at a volume of 16 ml and
incubated at 70°C for 5min. A 4-ml cocktail containing 25UofMoloney
Murine Leukemia Virus (M-MuLV) Reverse Transcriptase (New England
Biolabs, M0253S), 10 U of RNasin Plus (Promega, N261B), and 2 ml of
10x M-MuLV Reverse Transcriptase Reaction Buffer (New England
Biolabs, B0253S) were added, and samples were incubated at 42°C
for 1 hour and then at 95°C for 5 min. The cDNA was diluted and
used for real-time qPCR using the Power Eva qPCR SuperMix
Kit (Biochain, K5057400) following the manufacturer’s protocol.
qPCRwas performed on the StepOne PCR System (Applied Biosystems)
and analyzed with the DDCt method, as supplied by the manufac-
turer (Applied Biosystems). Rpl19 gene expression was used for inter-
nal normalization. Primer sequences used in this study are listed in
table S1.
Adenovirus
Adenovirus expressing scramble shRNA or shRNA targeting Ppp2ca
was purchased from Vector Biolabs. The targeting sequences for
Ppp2ca are CGACGAGTGTTTAAGGAAATA, which has been pre-
viously reported (53). Mice were injected by tail vein with 1 × 109
plaque-forming units (pfu) adenovirus/mouse.9 of 11
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Livers from treatedmice were harvested and fixed in 10% neutral buf-
fered formalin (Sigma, HT501128). Liver was embedded, sectioned,
and stained for hematoxylin and eosin by the University of California,
San Francisco (UCSF) Liver Center Pathology and Imaging Core
(San Francisco, CA). Images were taken at the UC Berkeley Biological
Imaging Facility (Berkeley, CA) using the Zeiss AxioImagerM1 at ×20
magnification. Each image shows a portion of the hepatic lobule. One
image from each treatment group was shown. At least two animals
were analyzed for each treatment group. Multiple sections were per-
formed for each liver.
Statistics
Data are expressed as SEM for each group, and comparisons were
analyzed by Student’s t test.htt
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Fig. S1. Expression analysis of genes involved in ceramide metabolism. 
WT and Angptl4-/- mice were treated with PBS or 0.42 mg/kg of dexamethasone (Dex) for 7 days. 
Hepatic gene expression patterns were determined by RT-qPCR. Error bars represent S.E.M., 
n=16 mice per group, and *p < 0.05. 
 
  
Fig. S2. Liver histology and WAT weight in dexamethasone-treated wild-type and Angptl4−/− 
mice. 
WT and Angptl4-/- mice were treated with PBS or 0.42 mg/kg of dexamethasone for 7 days prior 
to the collection of liver and eWAT. (A) Livers were fixed in 10% neutral buffered formalin and 
histology was performed by the UCSF Liver Center Pathology and Imaging Core (San Francisco, 
CA). For each mouse liver, multiple sections were prepared. Two animals per treatment group 
were processed for histological analysis. Representative images for each treatment group are 
  
shown. Scale bar (red, bottom left of top panel) represents 60 microns. (B) The graph shows the 
ratio of eWAT weight to total body weight. N=5-6 mice per group. 
 
Fig. S3. PP2A abundance and PKCζ activity in mice infected with adenovirus expressing 
Ppp2ca shRNA or treated with a PKCζ inhibitor. 
Wild-type mice were infected with 1x109 pfu/mouse of adenovirus expressing scramble shRNA 
or shRNA targeting Ppp2ca. Mice were treated with 0.42 mg/kg of dexamethasone for 7 days. 
Western blotting was performed to monitor Ppp2ca protein abundance (A) and PP2A activity was 
measured (B) in liver. (C) Wild-type mice were treated with 0.42 mg/kg of dexamethasone for 7 
days. 10 mg/kg of ACPD was injected into mice subcutaneously daily starting from day 4 for 4 
days. Western blotting was performed to monitor the amount of p-PKCζ, PKCζ and Gapdh 
(loading control) in liver.  
  
Table S1. qPCR primer list. 
Gene Forward Reverse 
Spt1 TACTCAGAGACCTCCAGCTG CACCAGGGATATGCTGTCATC 
Spt2 GGAGATGCTGAAGCGGAAC GTATGAGCTGCTGACAGGCA 
Cers2 GGCGCTAGAAGTGGGAAAC TCGAATGACGAGAAAGAGCA 
Cers3 GCTACACCTCTAGCAAATGCAC ATCTTTCAACCTGGCGCTCT 
Cers4 TGTCGTTGACGTTGAGTGAG AGCAGGCTTCACAGAATTTC 
Cers5 ACACTAGCCAATCAGGGCG GCTGCACTCTCAGGCTCC 
Cers6 ACAAAGCAAGATGGCAGGGA TCCGTGTTCTTCAGGTCTGC 
Des1 CACCGGTACCTCGGAGCGGA GTTTGGGATTGATGAACAGGGGT 
Sgms1 CTCATGAGGCCCAACAAGAT CACCTTCTTGGGTGACCAGT 
Smpd1 GGCGAGTACAGCAAGTGTGA AAGCCATTGACAGGAGTGCT 
Cerk CGGTACTGGTGTCGGAGATCA GTGAATGCGAACGGATTTTCC 
Sphk1 TCCTGGAGGAGGCAGAGATA CATTAGCCCATTCACCACCT 
Sgpp1 TACCCATTGGTGGACCTGAT CAGGGTATAAGCAGCGTGT 
Asah1 ATCAAAAGCTGCCTGGTATGAT TCCACCCAAGAAATATTCCAA 
Ugcg GGAATGGCCTTGTTCGGCT CGGCTGTTTGTCTGTTGCC 
Gba ATCTGCTTGGCTCACGAGTT TGTCGATGAAAGGGGTCTTC 
 
